Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Rachel E Sanborn; Michael J Pishvaian; Margaret K Callahan; Amy Weise; Branimir I Sikic; Osama Rahma; Daniel C Cho; Naiyer A Rizvi; Mario Sznol; Jose Lutzky; Julie E Bauman; Rhonda L Bitting; Alexander Starodub; Antonio Jimeno; David A Reardon; Thomas Kaley; Fabio Iwamoto; Joachim M Baehring; Deepa S Subramaniam; Jeanny B Aragon-Ching; Thomas R Hawthorne; Tracey Rawls; Michael Yellin; Tibor Keler

doi:10.1136/jitc-2022-005147

Citation Tools

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Sanborn RE, Pishvaian MJ, Callahan MK, et al

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Journal for ImmunoTherapy of Cancer 2022;10:e005147. doi: 10.1136/jitc-2022-005147

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password